Pierce 2018.

Study name	Reducing symptom burden in participants with heart failure with preserved ejection fraction using ubiquinol and/or D‐ribose
Methods	Randomized, double‐blinded (participant, investigator), placebo‐controlled, parallel trial
Participants	Adults, 50 years and older, meeting the following inclusion criteria: Diagnosed with heart failure with preserved ejection fraction within a 6‐month period New York Heart Association (NYHA) Classification II to III heart failure Have left ventricular ejection fraction (EF) ≥ 50% documented by an echocardiogram Have a telephone or reliable phone contact Have their own means of transportation to the study site
Interventions	Arm 1 (placebo only): placebo pills that are 300 mg capsules, two times daily plus 15 grams placebo powder, mixed with non‐carbonated liquid, one time daily Arm 2 (coenzyme Q10 only): 300 mg capsules of coenzyme Q10, two times daily plus 15 grams placebo powder, mixed with non‐carbonated liquid, one time daily Arm 3 (D‐ribose only): 15 grams D‐Ribose powder, mixed with non‐carbonated liquid, one time daily plus placebo pills that are 300 mg capsules, two times daily Arm 4 (coenzyme Q10 + D‐ribose): 300 mg capsules of coenzyme Q10, two times daily plus 15 grams D‐Ribose powder, mixed with non‐carbonated liquid, one time daily Interventions administered for up to 12 weeks
Outcomes	Primary outcomes: change in health status of participants, measured by the Kansas City Cardiomyopathy Questionnaire Secondary outcomes: Change in vigour measured using the Vigor subscale from the Profile of Mood States (POMS) questionnaire Left ventricular diastolic function Change in 6‐minute walk test Change in venous blood B‐type natriuretic peptide (BNP) levels Change in lactate/adenosine triphosphate (ATP) ratio
Starting date	February 5, 2018
Contact information	Faith Rahman (frahman2@kumc.edu) Janet Pierce, PhD (jpierce@kumc.edu)
Notes